The type II fatty acid synthase pathway ofPlasmodium falciparumis a validated unique target for developing novel antimalarials because of its intrinsic differences from the type I pathway operating in humans. b-Ketoacyl-acyl carrier protein reductase is the only enzyme of this pathway that has no isoforms and thus selective inhibitors can be developed for this player of the pathway.